CLPT
Clearpoint Neuro Inc
$
15.810
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
16.240
Open
14.970
VWAP
15.35
Vol
2.05M
Mkt Cap
449.37M
Low
14.710
Amount
31.47M
EV/EBITDA(TTM)
--
Total Shares
27.42M
EV
506.25M
EV/OCF(TTM)
--
P/S(TTM)
14.87
ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The Company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The Company also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
11.40M
+34.35%
-0.190
-13.64%
10.35M
+33.19%
-0.185
-7.5%
9.60M
+18.2%
-0.200
+11.11%
Estimates Revision
The market is revising Upward the revenue expectations for ClearPoint Neuro, Inc. (CLPT) for FY2025, with the revenue forecasts being adjusted by 0.13% over the past three months. During the same period, the stock price has changed by 46.12%.
Revenue Estimates for FY2025
Revise Upward
+0.13%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.26%
In Past 3 Month
Stock Price
Go Up
+46.12%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast CLPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLPT is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.810
Low
30.00
Averages
30.00
High
30.00
Current: 15.810
Low
30.00
Averages
30.00
High
30.00
B. Riley
Buy
maintain
$20 -> $28
2025-04-25
Reason
B. Riley
Price Target
$20 -> $28
2025-04-25
maintain
Buy
Reason
B. Riley raised the firm's price target on ClearPoint Neuro to $28 from $20 and keeps a Buy rating on the shares following a transfer of coverage. ClearPoint is a medical device company focused on providing image-guided navigation for minimally invasive neuro procedures, the analyst tells investors in a research note. The firm says the company's core business continues to grow over 20% annually, and that it expects significant growth in the future as biopharma partnerships progress towards regulatory approvals and commercial launches.
Stifel
Mathew Blackman
Strong Buy
Maintains
$19 → $25
2025-04-01
Reason
Stifel
Mathew Blackman
Price Target
$19 → $25
2025-04-01
Maintains
Strong Buy
Reason
B. Riley Securities
Neil Chatterji
Strong Buy
Maintains
$15 → $20
2025-01-28
Reason
B. Riley Securities
Neil Chatterji
Price Target
$15 → $20
2025-01-28
Maintains
Strong Buy
Reason
Lake Street
Frank Takkinen
Strong Buy
Maintains
$17 → $30
2025-01-21
Reason
Lake Street
Frank Takkinen
Price Target
$17 → $30
2025-01-21
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Clearpoint Neuro Inc (CLPT.O) is -24.15, compared to its 5-year average forward P/E of -17.82. For a more detailed relative valuation and DCF analysis to assess Clearpoint Neuro Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-17.82
Current PE
-24.15
Overvalued PE
-8.58
Undervalued PE
-27.06
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-23.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-10.98
Undervalued EV/EBITDA
-35.38
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Overvalued
5Y Average PS
11.44
Current PS
18.23
Overvalued PS
17.59
Undervalued PS
5.29
Financials
Annual
Quarterly
FY2025Q3
YoY :
+9.10%
8.86M
Total Revenue
FY2025Q3
YoY :
+2.01%
-5.28M
Operating Profit
FY2025Q3
YoY :
+18.44%
-5.89M
Net Income after Tax
FY2025Q3
YoY :
+16.67%
-0.21
EPS - Diluted
FY2025Q3
YoY :
+174.15%
-3.32M
Free Cash Flow
FY2025Q3
YoY :
+5.90%
63.20
Gross Profit Margin - %
FY2025Q3
YoY :
+35.00%
-40.27
FCF Margin - %
FY2025Q3
YoY :
+8.56%
-66.48
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
714.0K
USD
1
3-6
Months
543.4K
USD
3
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
714.0K
USD
1
3-6
Months
543.4K
USD
3
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CLPT News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
17:42:30
ClearPoint Neuro Purchases Irras Holdings; Financial Details Not Revealed
2025-09-04 (ET)
2025-09-04
16:37:50
ClearPoint Neuro Receives Approval for Prism Neuro Laser Therapy with 1.5T MRI Guidance
2025-06-03 (ET)
2025-06-03
08:54:13
Lake Street says AMT-130 could be 'significantly impactful' for ClearPoint
Sign Up For More Events
Sign Up For More Events
News
9.5
11-06SeekingAlphaPinnedClearPoint Neuro, Inc. Reports GAAP EPS of -$0.21, Falling Short by $0.01; Revenue of $8.86M Misses Expectations by $0.74M
2.0
11-03BenzingaMajor Stocks, Including Kimberly-Clark and Vertex, Decline in Monday's Pre-Market Trading
4.5
10-03TipRanksFriday's Major Stock Market Highlights: Morning News Summary!
Sign Up For More News
People Also Watch
DGICA
Donegal Group Inc
19.240
USD
+1.10%
OTLY
Oatly Group AB (publ)
15.190
USD
+0.07%
OFLX
Omega Flex Inc
27.000
USD
-2.07%
OBE
Obsidian Energy Ltd
5.860
USD
+3.53%
PKST
Peakstone Realty Trust
14.950
USD
+4.47%
PSNL
Personalis Inc
6.930
USD
-3.55%
SPMC
Sound Point Meridian Capital Inc
16.460
USD
+0.12%
HYLN
Hyliion Holdings Corp
2.120
USD
+1.92%
KMDA
Kamada Ltd
6.660
USD
+0.60%
KALV
Kalvista Pharmaceuticals Inc
10.780
USD
-1.01%
FAQ
What is Clearpoint Neuro Inc (CLPT) stock price today?
The current price of CLPT is 15.81 USD — it has decreased -13.27 % in the last trading day.
What is Clearpoint Neuro Inc (CLPT)'s business?
What is the price predicton of CLPT Stock?
What is Clearpoint Neuro Inc (CLPT)'s revenue for the last quarter?
What is Clearpoint Neuro Inc (CLPT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Clearpoint Neuro Inc (CLPT)'s fundamentals?
How many employees does Clearpoint Neuro Inc (CLPT). have?